Evidence map›Paper›PMID 22314134›Full record

ArticleVaccine2012

A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Liang Xiao, Jocelyn Kim, Matthew Lim, Bingbing Dai, Lili Yang, Steven G Reed, David Baltimore, Pin Wang

Abstract read
In one paragraph

Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Polysaccharide Isolated FromFrontiers in pharmacology · 2021
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Liang XiaoMork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA 90089, USA.
Jocelyn Kim
Matthew Lim
Bingbing Dai
Lili Yang
Steven G Reed
David Baltimore
Pin Wang
University of Southern California · USCalifornia Institute of Technology · USInfectious Disease Research Institute · US

Funding

Transduction of Hematopoietic Stem Cells for Enhanced Immunotherapy of MelanomaP01CA132681 · NCI · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI BALTIMORE, DAVID · 2010 to 2014
$14.4M
Targeting lentiviruses to infect chosen cellsR01AI068978 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WANG, PIN · 2006 to 2010
$2.9M
NCI NIH HHS P01 CA132681NCI NIH HHS P01CA132681NIAID NIH HHS R01 AI068978NIAID NIH HHS R01AI68978
6 · The paper itself

Abstract

TLR4 agonists can be used as adjuvants to trigger innate immune responses of antigen-presenting cells (APCs) such as dendritic cells (DCs) to enhance vaccine-specific immunity. Adjuvant effects of TLR4 agonists are mediated by downstream signaling controlled by both MyD88 and TRIF adapter proteins. In this study, we investigated the adjuvanting capacity of glucopyranosyl lipid A (GLA), a chemically synthesized TLR4 agonist, to boost antigen-specific immunity elicited by DC-directed lentiviral vectors (DC-LV). We found that stimulation by this agonist in vitro can activate DCs in a TLR4-dependent manner. The agonist can significantly boost DC-LV-induced humoral and cellular immune responses, resulting in better antitumor reactions in response to tumor challenges. We observed that the adjuvant-mediated enhancement of cytotoxic CD8(+) T cell responses is CD4(+) T cell-dependent and determined that in vitro the agonist stimulation involves the participation of both MyD88 and TRIF pathways to activate DCs. In vivo immunization study however revealed that adjuvant effects depend more on the MyD88 signaling as TRIF(-/-) mice but not MyD88(-/-) mice were able to maintain the enhanced CD8(+) T cell responses upon DC-LV immunization. Thus, our study supports the use of this TLR4 agonist as a potent adjuvant candidate for boosting DC-LV immunization.

Indexed as

Genetic VectorsAdaptor Proteins, Vesicular TransportAdjuvants, ImmunologicAnimalsDendritic CellsFemaleImmunity, HumoralLentivirusLipid AMiceMice, 129 StrainMice, Inbred C57BLMice, KnockoutMyeloid Differentiation Factor 88Signal TransductionT-LymphocytesAdaptor Proteins, Vesicular TransportAdjuvants, ImmunologicLipid AMyeloid Differentiation Factor 88Ticam1 protein, mouseToll-Like Receptor 4

Identifiers

PMID22314134
PMCPMC3360926
OpenAlexW2071484872

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.